Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Market Closed - Nasdaq
Other stock markets
 15:59:41 2024-05-29 EDT 		5-day change 1st Jan Change
18.66 USD -2.56% Intraday chart for HUTCHMED (China) Limited -6.23% +3.04%
05-24 HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
05-20 Hutchmed (China) Chairman Resigns, Successor Named MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology
CI
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
CI
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies
AN
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
CI
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
CI
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug
MT
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer
MT
Hutchmed to Present New Data at US Cancer Research Conference
MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024
CI
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination
MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
CI
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
CI
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug
MT
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
CI
Hutchmed Returns to Profit in 2023; EPS Tops Estimate
MT
EARNINGS: Hutchmed revenue surges, Craven House's loss widens
AN
Hutchmed Swings to 2023 Profit as Revenue Increases
MT
Hutchmed (China) Swings to Profit in FY23; Revenue Soars
MT
HUTCHMED Limited Provides Revenue Guidance for the Year 2024
CI
HUTCHMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. News HUTCHMED (China) Limited
  6. Highlights